Prognostic impact of c-KIT mutations in core binding factor leukemias: an Italian retrospective study
Authors:
- Roberto CairoliRCRoberto Cairoli
- Alessandro BeghiniABAlessandro Beghini
- Giovanni GrilloGGGiovanni Grillo
- Gianpaolo NadaliGNGianpaolo Nadali
- Francesca EliceFEFrancesca Elice
- Carla Barbara RipamontiCRCarla Barbara Ripamonti
- Patrizia ColapietroPCPatrizia Colapietro
- Michele NichelattiMNMichele Nichelatti
- Laura PezzettiLPLaura Pezzetti
- Monia LunghiMLMonia Lunghi
- Antonio CuneoACAntonio Cuneo
- Assunta ViolaAVAssunta Viola
- 1 May 2006
- journal article
- research article
- Published by American Society of Hematology in Blood
- Vol. 107 (9) , 3463-3468
Abstract
Distinct forms of tyrosine kinase domain (TKD), juxtamembrane domain, exon 8, and internal tandem duplication (ITD) mutations of c-KIT, were observed in about 46% of core binding factor leukemia (CBFL) patients. To evaluate their prognostic significance, 67 adult patients with CBFL were analyzed to ascertain the c-KIT mutation status. In acute myeloid leukemia (AML) with t(8;21), the presence of c-KIT TKD mutation at codon 816 (TKD816) was associated with a high white blood cell count at diagnosis (median, 29.60 × 109/L) and a higher incidence (33%) of extramedullary leukemia (EML) during the course of the disease. Data also showed that the TKD816 mutated patients (n = 12) had a significantly higher incidence of relapse and a lower overall survival (OS) at 24 months, compared with the 17 c-KIT unmutated (c-KIT–) patients (90% vs 35.3%, P = .002; 25% vs 76.5%, P = .006, respectively). No difference in relapse incidence (P = .126) and OS (P = .474) was observed between the c-KIT mutated other than TKD816 (n = 7) and the c-KIT– patients. These findings indicate that c-KIT TKD816 mutation has a negative impact on the outcome of AML with t(8;21).Keywords
This publication has 14 references indexed in Scilit:
- Mutations in the receptor tyrosine kinase pathway are associated with clinical outcome in patients with acute myeloblastic leukemia harboring t(8;21)(q22;q22)Leukemia, 2005
- Prognostic implication of FLT3 and Ras gene mutations in patients with acute promyelocytic leukemia (APL): a retrospective study from the European APL GroupLeukemia, 2005
- Extramedullary Leukemia in Children With Newly Diagnosed Acute Myeloid LeukemiaJournal of Pediatric Hematology/Oncology, 2003
- Incidence and prognosis of c‐KIT and FLT3 mutations in core binding factor (CBF) acute myeloid leukaemiasBritish Journal of Haematology, 2003
- Prognosis of inv(16)/t(16;16) acute myeloid leukemia (AML): a survey of 110 cases from the French AML IntergroupBlood, 2003
- C-Kit point mutations in core binding factor leukemias: correlation with white blood cell count and the white blood cell indexLeukemia, 2003
- Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461)Blood, 2002
- Amplification of a novel c-Kit activating mutation Asn822-Lys in the Kasumi-1 cell line: a t(8;21)-Kit mutant model for acute myeloid leukemiaThe Hematology Journal, 2002
- A white blood cell index as the main prognostic factor in t(8;21) acute myeloid leukemia (AML): a survey of 161 cases from the French AML IntergroupBlood, 2002
- Activating mutation of D835 within the activation loop of FLT3 in human hematologic malignanciesBlood, 2001